Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 294,644 | 335,001 | 207,742 | 181,227 | 1,535 |
| Cost of Goods | 182,052 | 145,336 | 7,768 | N/A | N/A |
| Gross Profit | 112,592 | 189,665 | 199,974 | 181,227 | 1,535 |
| Operating Expenses | 490,470 | 476,289 | 378,903 | 257,901 | 137,995 |
| Operating Income | -377,826 | -286,288 | -178,161 | -76,674 | -136,460 |
| Interest Expense | 8,871 | -792 | 0 | 0 | 0 |
| Other Income | 1,856 | -794 | 6,235 | 3,003 | 713 |
| Pre-tax Income | -384,841 | -286,290 | -171,926 | -73,671 | -135,747 |
| Income Tax | N/A | -6,631 | -28,338 | N/A | N/A |
| Net Income Continuous | -384,841 | -279,659 | -143,588 | -73,671 | -135,747 |
| Net Income | $-384,841 | $-279,659 | $-143,588 | $-73,671 | $-135,747 |
| EPS Basic Total Ops | -2.78 | -2.36 | -2.47 | -1.69 | -3.60 |
| EPS Basic Continuous Ops | -2.78 | -2.36 | -2.47 | -1.69 | -3.60 |
| EPS Diluted Total Ops | -2.78 | -2.36 | -2.47 | -1.69 | -3.60 |
| EPS Diluted Continuous Ops | -2.78 | -2.36 | -2.47 | -1.69 | -3.60 |
| EPS Diluted Before Non-Recurring Items | -1.93 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-228,756 | $-248,461 | $-176,972 | $-75,447 | $-135,670 |